Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 8,210 shares of common stock on July 14, 2026, in two transactions at weighted-average prices of $40.57 and $39.72, executed under Rule 10b5-1 trading plans adopted on March 27, 2026. Following these sales, he holds 539,817 shares directly. Additional shares are held in two irrevocable trusts (20,729 and 81,729 shares), for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Rapport Therapeutics Chief Operating Officer Cheryl Gault reported open-market sales totaling 10,000 shares of common stock on June 30, 2026. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between about $40 and $43 per share.
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of common stock under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 8,220 shares on June 29, 2026 in two transactions at weighted average prices of $39.77 and $40.34 per share.
Following these sales, Ceesay held 548,027 shares of common stock directly. Additional shares are held indirectly by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust, for which he disclaims beneficial ownership except to any pecuniary interest.
Rapport Therapeutics, Inc. director John Maraganore received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, he holds 15,200 options directly.
The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Rapport Therapeutics director Robert J. Perez received a grant of stock options for 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The shares underlying this option vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders of Rapport Therapeutics, subject to his continued service on that vesting date. Following this grant, he holds 15,200 derivative securities directly.
Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock. The options carry an exercise price of $35.21 per share and expire on June 10, 2036.
According to the terms, the 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through that vesting date. Following this grant, he holds 15,200 stock options directly.
Rapport Therapeutics director Paul M. Silva received a grant of stock options as equity compensation. The award covers 15,200 options to buy common stock at an exercise price of $35.21 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.
Rapport Therapeutics director James Healy received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The 15,200 underlying shares vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics' next Annual Meeting of Stockholders, as long as Healy continues serving the company through that vesting date. After this award, he holds 15,200 derivative securities from this grant.